Episode 24 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Joseph R. Berger, MD, of the University of Pennsylvania. [WATCH TIME: 7 minutes]
Advice to community physicians and neurologists who play a role in caring for patients with multiple sclerosis in community practices on optimizing therapy with high-efficacy and newer treatment options.
The director of the Pediatric Epilepsy Program is joined by an MD candidate from Weill Cornell Medicine to discuss the protocol used to treat patients with status epilepticus.
The vice president of science and medical at Dreem offered his opinion on how the company’s headband device can improve how sleep studies are conducted.
The director of the Headache Center of Southern California discussed research opportunities for layered treatment approaches in migraine.
Hendrix spoke to the challenges he and colleagues come across, as well as his hope for the promising future.
Advocacy organization Cure SMA provides guidance for health care providers caring for patients with SMA during the ongoing COVID-19 pandemic.
Noninvasive neuromodulation with TAPS is a safe and effective tool that offers particular utility in the age of COVID-19 when other treatment options may be less accessible.
A novel gene therapy has demonstrated impressive early results in a small sample of 3 children with Duchenne muscular dystrophy.
The diagnosis of Parkinson disease may seem straightforward at first, requiring neurologists to rely on their eyes and hands, but the treatment process can present challenges for both physicians and patients.
The head of the Stroke Program and Medical Director of the Comprehensive Stroke Center at Cleveland Clinic provided perspective on the ENRICH trial, the first positive surgical trial for intracerebral hemorrhage. [WATCH TIME: 5 minutes]
The chair of the Department of Neurosurgery at Banner-University Medical Center discusses the current state of the science being done in the realm of epilepsy surgery.
The postdoctoral fellow at the University of Miami Miller School of Medicine detailed the role that increased APOE ε4 expression can have on future research and clinical care.
The vice president of AstraZeneca’s Cardiovascular and Metabolic Diseases Portfolio detailed the results from the phase 3 THALES trial, and where ticagrelor stands among other FDA approved stroke treatments.
Drs Atri, Cohen, Sabbagh and McDade share their enthusiasm and optimism about the future outlook for Alzheimer’s disease.
The group medical director of neuroscience at Genentech spoke to the findings recently presented at the 6th Annual Meeting of the European Academy of Neurology.
Stuart H. Isaacson, MD, FAAN, offers insight into the challenges faced when attempting to achieve long-term symptom control for patients with Parkinson disease.
The clinical professor of neurology at Albert Einstein College of Medicine spoke to the findings of the OVERCOME study, and how recent literature has suggested that improper prescriptions and medication use in migraine have been ongoing in spite of the current recommendations.
The Director of Behavioral Medicine at the Mellen Center for MS Treatment and Research at the Cleveland Clinic spoke about how she approaches fatigue in MS from a behavioral standpoint.
Despite some mistrusting the abilities of imaging to aid in therapeutic development, a new MRI method could better inform the anatomical understanding of the striatum.
An expert discusses takeaways about the anti-CD20 monoclonal antibody class of disease-modifying therapies for patients with relapsing multiple sclerosis through the lens of ofatumumab (Kesimpta; Novartis).
The spine surgeon in the Center for Spine Health at Cleveland Clinic spoke to the importance of improving patient-reported outcomes and ensuring consistent communication with patients undergoing spine surgery.
After years of failed drug development, the thoughts of disease-modifying therapies for Alzheimer disease are starting to become real.
The professor and head of the department of neurology at the University of Minnesota discussed what multiple independent contact current-controlled devices offer physicians conducting deep brain stimulation.
Mia Minen, MD, MPH, sat down for an interview to discuss why behavioral therapies could be an effective and easily accessible treatment for posttraumatic headaches following events like concussions.